Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients.

Podcast Episode Summary

Introduction

Dr. Warrick Bishop, a cardiologist, author, and CEO of the Healthy Heart Network, hosts this episode focused on blood thinners and anticoagulation therapy. With heart disease claiming one Australian life every 20 minutes, Dr. Bishop aims to educate listeners on critical medications that prevent heart attacks and strokes. This episode provides practical guidance on when blood thinners are needed, which types are appropriate for different conditions, and important considerations around their use and discontinuation.

Key Takeaways:

• Anti-platelet agents (aspirin, clopidogrel, prasugrel) are critical for managing atherosclerosis by reducing clot formation in arteries and preventing heart attacks and strokes.

• Patients requiring stent implantation typically need dual antiplatelet therapy for up to a year, with the duration and specifics determined by the interventionalist who placed the stent.

• Warfarin remains the superior choice for two specific conditions: rheumatic heart disease with mitral stenosis and atrial fibrillation, and mechanical heart valves, where NOACs have not demonstrated equivalent effectiveness.

• Non-vitamin K oral anticoagulants (NOACs) are the preferred first-line treatment for non-valvular atrial fibrillation, offering equal or greater effectiveness than warfarin with better convenience and fewer side effects.

• NOACs work rapidly and are highly effective for treating pulmonary embolus (PE) and deep vein thrombosis (DVT), with therapeutic levels achieved quickly.

• Decisions to stop anticoagulation before surgery should never be made unilaterally but require a three-way conversation between the patient, cardiologist, and surgeon to weigh bleeding risks against clot formation risks.

• Stopping dual antiplatelet therapy post-stent must be guided by the original interventionalist, as individual patient factors and procedural nuances may warrant longer or shorter treatment duration than standard protocols.

• Pre-surgical anticoagulation management requires documented informed consent discussions with patients to ensure they understand that no zero-risk position exists when reducing anticoagulation.